ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

20 links0 made here, not in the record30 judgments2 judges (the rules as one: Rule based)0 record changes seen
Claude Opus 5.5Rule basedReplaced, or read an older version
Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT03228667QUILT-3.055: A Study ofCombination Immunotherapiesin Patients Who HavePreviously ReceivedTreatment With ImmuneCheckpoint InhibitorsImmunityBio, Inc.Phase 2 · active not recruitinRECORDThe record itselfVersions seen nightly since Sep 25, 2…›No new version seen since tracking began Sep 25, 2026.CONDITIONSCarcinoma, Non-Small-Cell L…The registry's MeSH filing›Nov 14 · Rule based · Finest filed termAs of now · Rule based · Main conditionMain conditionSmall Cell Lung CarcinomaThe registry's MeSH filing›Nov 14 · Rule based · Finest filed termFinest filed termCarcinoma, Transitional CellThe registry's MeSH filing›Nov 14 · Rule based · Finest filed termFinest filed termSquamous Cell Carcinoma of …The registry's MeSH filing›Nov 14 · Rule based · Finest filed termFinest filed termCarcinoma, Merkel CellThe registry's MeSH filing›Nov 14 · Rule based · Finest filed termFinest filed termMelanomaThe registry's MeSH filing›Nov 14 · Rule based · Finest filed termFinest filed termCarcinoma, Renal CellThe registry's MeSH filing›Nov 14 · Rule based · Finest filed termFinest filed termStomach NeoplasmsThe registry's MeSH filing›Nov 14 · Rule based · Finest filed termFinest filed termUterine Cervical NeoplasmsThe registry's MeSH filing›Nov 14 · Rule based · Finest filed termFinest filed termCarcinoma, HepatocellularThe registry's MeSH filing›Nov 14 · Rule based · Finest filed termFinest filed termMicrosatellite InstabilityThe registry's MeSH filing›Nov 14 · Rule based · Finest filed termFinest filed termTurcot syndromeThe registry's MeSH filing›Nov 14 · Rule based · Finest filed termFinest filed termColorectal NeoplasmsThe registry's MeSH filing›Nov 14 · Rule based · Wider: a narrower term is filedWider: a narrower term is filedDRUGSNogapendekin alfa inbakiceptEntry “N-803 + Pembrolizumab”, read b…›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedPembrolizumabEntry “N-803 + Pembrolizumab”, read b…›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedNivolumabEntry “N-803 + Nivolumab”, read by ou…›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · TestedTestedAtezolizumabEntry “N-803 + Atezolizumab”, read by…›Nov 2 · Claude Opus 5.5 · TestedNov 3 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · TestedTestedAvelumabEntry “N-803 + Avelumab”, read by our…›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedDurvalumabEntry “N-803 + Durvalumab”, read by o…›Nov 2 · Claude Opus 5.5 · TestedNov 3 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · TestedTestedDocetaxelEntry “N-803 + Docetaxel + Pembrolizu…›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTested

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

Nogapendekin alfa inbakicept

From the registry record2 judgments on this link
Role in the study, from the registry to what was judged
RegistryEntry “N-803 + Pembrolizumab”the record gives no role
→judged=agrees
How the 2 judgments split100%of judgments with a known value say Tested
Tested · 2

All judgments on this study

WhenLinkJudgeDecisionState
Nov 2Nogapendekin alfa inbakiceptClaude Opus 5.5TestedCurrent
Nov 2PembrolizumabClaude Opus 5.5TestedCurrent
Nov 2NivolumabClaude Opus 5.5BackgroundCurrent
Nov 2AtezolizumabClaude Opus 5.5TestedReplaced
Nov 2AvelumabClaude Opus 5.5TestedCurrent
Nov 2DurvalumabClaude Opus 5.5TestedReplaced
Nov 2DocetaxelClaude Opus 5.5TestedCurrent
Nov 3AtezolizumabClaude Opus 5.5BackgroundCurrent
Nov 3DurvalumabClaude Opus 5.5BackgroundCurrent
Nov 14Carcinoma, Non-Small-Cell LungRule based · condition-kind ruleFinest filed termCurrent
Nov 14Small Cell Lung CarcinomaRule based · condition-kind ruleFinest filed termCurrent
Nov 14Carcinoma, Transitional CellRule based · condition-kind ruleFinest filed termCurrent
Nov 14Squamous Cell Carcinoma of Head and NeckRule based · condition-kind ruleFinest filed termCurrent
Nov 14Carcinoma, Merkel CellRule based · condition-kind ruleFinest filed termCurrent
Nov 14MelanomaRule based · condition-kind ruleFinest filed termCurrent
Nov 14Carcinoma, Renal CellRule based · condition-kind ruleFinest filed termCurrent
Nov 14Stomach NeoplasmsRule based · condition-kind ruleFinest filed termCurrent
Nov 14Uterine Cervical NeoplasmsRule based · condition-kind ruleFinest filed termCurrent
Nov 14Carcinoma, HepatocellularRule based · condition-kind ruleFinest filed termCurrent
Nov 14Microsatellite InstabilityRule based · condition-kind ruleFinest filed termCurrent
Nov 14Turcot syndromeRule based · condition-kind ruleFinest filed termCurrent
Nov 14Colorectal NeoplasmsRule based · condition-kind ruleWider: a narrower term is filedCurrent
Nov 18Nogapendekin alfa inbakiceptRule based · role ruleTestedAgrees
Nov 18PembrolizumabRule based · role ruleTestedAgrees
Nov 18NivolumabRule based · role ruleTestedCurrent
Nov 18AtezolizumabRule based · role ruleTestedCurrent
Nov 18AvelumabRule based · role ruleTestedAgrees
Nov 18DurvalumabRule based · role ruleTestedCurrent
Nov 18DocetaxelRule based · role ruleTestedAgrees
As of nowCarcinoma, Non-Small-Cell LungRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.

How a condition link is counted

For each condition a study is filed under: whether it is the study's own condition at the finest the study states it, a wider one, a general category, or filed by mistake; and whether it is the main condition, a setting the study names, or only how it was filed.

A decision on file for one study overrides it, with who made it and when.